Measuring What Matters: RECIST Response Does Not Predict HRQoL in Early-Phase Clinical Trials
: HRQoL change is largely independent of radiologic tumour response and therapy type in EPCT participants. Patients experienced a HRQoL decline despite tumour response. Incorporating patient-reported outcomes alongside RECIST and safety outcomes is important to fully capture the impact of investigational therapies and guide patient-centred trial designs.
Authors
- Joseph Descallar (ORCID: https://orcid.org/0000-0002-6919-4865)
- Martin Hong (ORCID: https://orcid.org/0000-0002-2327-4261)
- Weng Ng (ORCID: https://orcid.org/0000-0003-2354-1857)
- Charlotte Lemech (ORCID: https://orcid.org/0000-0002-5399-9431)
- Joe Wei (ORCID: https://orcid.org/0000-0003-1944-1079)
- Udit Nindra (ORCID: https://orcid.org/0000-0002-2612-9502)
- Aflah Roohullah (ORCID: https://orcid.org/0000-0002-4480-2529)
- Kate Wilkinson (ORCID: https://orcid.org/0000-0001-9666-2647)
- Abhijit Pal
- Walid Zwieky
- CHRISTINA TENG
- Jun Hee Hong (ORCID: https://orcid.org/0000-0002-9977-7471)
- J. Tang
- Jessie Nguyen
- Andrew Killen
- Adam Cooper
Institutions
- Liverpool Hospital (AU)
- Ingham Institute (AU)
- Western Sydney University (AU)
- Neuroscience Research Australia (AU)
Publication Details
- Journal
- Cancers
- Published
- 2026-04-14
- DOI
- https://doi.org/10.3390/cancers18081242
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00